ImmuCell reported FY 2025 product sales of USD 27.6 million (+4.3%) and a gross profit margin of 41.4% of product sales. Net loss for FY 2025 was USD 1.0 million, or (USD 0.12) per basic share, while net operating income was USD 1.6 million; EBITDA was USD 2.2 million. For Q4 2025, product sales were USD 7.6 million and net loss was USD 2.8 million, or (USD 0.31) per basic share. ImmuCell said FY 2025 results reflected higher volumes, manufacturing efficiencies and price realization, and noted non-recurring items affecting net loss including a USD 2.7 million write-down of Re-Tain assets, USD 0.7 million of colostrum inventory write-downs, and USD 0.3 million of CEO transition expenses, partially offset by USD 0.4 million of one-time insurance proceeds. The company highlighted increased average monthly output to about 380,000 units in FY 2025 and said it is focusing strategy on its on-market First Defense franchise. As of Dec. 31, 2025, cash and cash equivalents were USD 3.8 million, net working capital was USD 13.0 million, and stockholders’ equity was USD 27.1 million.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. ImmuCell Corporation published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202603041605PRIMZONEFULLFEED9665913) on March 04, 2026, and is solely responsible for the information contained therein.